.png)
← All articlesMost people who stop a GLP-1 do not stop because it failed. They stop because week three felt awful, nobody had told them it would, and quitting seemed easier than asking. That is the most preventable failure in medical weight loss, and it is almost always a management problem rather than a medication problem.
This is the guide we wish every patient had before their first injection: what the clinical data actually shows about how common these effects are, how to manage each one, the single lever that matters more than all the rest, and the specific symptoms that mean you should stop reading and call us.
Common enough that you should expect something, and mild enough, in most cases, that it passes.
In the clinical trials behind the FDA-approved semaglutide product for weight management, 73% of treated patients reported a gastrointestinal side effect, compared with 47% on placebo. The most frequently reported were nausea (44% vs. 16% on placebo), diarrhea (30% vs. 16%) and vomiting (25% vs. 6%). Severe gastrointestinal reactions were uncommon but real: 4.1% of treated patients versus 0.9% on placebo.
For the FDA-approved tirzepatide product, the most commonly reported effects were nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, injection-site reactions, fatigue, hypersensitivity reactions, burping, hair loss and reflux. Discontinuation because of gastrointestinal effects occurred in 3.3% of patients at the 10 mg dose and 4.3% at 15 mg, against 0.5% on placebo.
Read those discontinuation numbers again, because they are the encouraging part. Even at the highest doses, more than 95% of people stayed on treatment. Side effects are common; being forced off by them is not.
One important note on where these figures come from. The percentages above are drawn from the FDA-approved prescribing information for the brand-name products. A personalized compounded formulation is not the same product and does not carry FDA-approved labeling, so those exact incidence figures cannot simply be transferred to it. We cite them because they are the best-quality data available on how these molecules behave in large populations, not as a claim about any specific preparation.
Nearly all of it traces to one mechanism. GLP-1 receptor agonists slow gastric emptying, so food leaves your stomach more slowly than it used to. That is a large part of why you feel full sooner and stay full longer, which is the therapeutic effect you are paying for. It is also why you feel nauseated if you eat the volume you ate before, or eat something fatty, or lie down afterwards.
Understanding that changes how you respond. The goal is not to fight the slower stomach. It is to eat in a way that suits it.
There are two predictable windows:
For most people symptoms ease as the body adapts at a given dose. If they are not easing, that is information worth acting on rather than something to endure quietly.
The highest-yield changes are behavioural, and they work:
Occasional vomiting during titration is not unusual. What matters is fluid. Sip steadily through the day rather than drinking large volumes at once. If you cannot keep fluids down for more than a day, call us. That is the pathway by which this becomes genuinely dangerous, which we cover below.
Less discussed than nausea, and often more persistent. Increase water intake, increase dietary fibre gradually, and move more, since physical activity has a real effect on transit time. A stool softener may be appropriate; ask us rather than layering on laxatives indefinitely. If you were already prone to constipation before starting, tell us at your first visit so we can address it up front rather than after it becomes a problem.
Usually early and self-limiting. Keep fluids up, favour bland foods, and let us know if it persists beyond a few days or is severe.
Both follow from slower gastric emptying. Smaller meals, staying upright after eating, and not eating close to bedtime address most of it.
Often a knock-on effect of eating substantially less rather than the medication itself, and sometimes a sign you are underfuelling or under-hydrating. It is worth checking that your protein intake has not collapsed alongside your overall intake.
Titration. Clinical guidance for managing gastrointestinal effects on these medications comes down to a principle: start low and go slow.
Where symptoms persist despite the dietary measures above, expert consensus recommends deferring the dose increase and holding at the current dose for a further two to four weeks before attempting to move up again.
This is worth internalising because it runs against most people's instincts. Patients often assume the schedule is fixed and their job is to tough it out. It is not fixed. Holding a dose longer is a normal, clinically appropriate adjustment, and it is very often the difference between someone who stays on treatment for a year and someone who quits in month two. Tell us what you are experiencing and we will adjust the plan around it.
FDA has alerted providers, compounders and patients to dosing errors involving compounded injectable semaglutide, some resulting in overdoses with severe nausea, severe vomiting and severe hypoglycemia. Because semaglutide has a half-life of roughly one week, an overdose can require a prolonged period of observation and treatment.
The practical implication is simple and applies to any preparation: your dose, your syringe markings and your titration schedule should come from your provider, and you should never estimate. If you are ever uncertain how to measure or administer your dose, stop and ask us before injecting. There is no such thing as a silly question here.
Most side effects are a nuisance. These are not. Contact us promptly, or seek emergency care where the symptom is severe:
The FDA-approved labeling for both molecules carries a boxed warning regarding thyroid C-cell tumors. In rodents, semaglutide causes thyroid C-cell tumors at clinically relevant exposures; whether it does so in humans is unknown, as the human relevance of that rodent finding has not been determined. These medications are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma, or with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Caution also applies if you have a history of pancreatitis, significant gastrointestinal disease, or diabetic retinopathy. These medications are not for use in pregnancy. This is exactly what a proper intake visit and baseline lab work are for: screening before the first injection, not after a problem appears.
Side effect management is one part of doing this properly. Two others matter just as much:
If skin changes are on your mind as the weight comes off, we have addressed that too in loose skin after GLP-1 weight loss.
Every symptom in this guide is more manageable with a provider who knows your history and can adjust your plan. That is the difference between a supervised program and a prescription mailed to your door.
If you are struggling with side effects on a current program, or considering starting one and want to understand what to expect first, we would rather have that conversation before it becomes a reason to quit. Book a medical weight loss consultation at Contour Medical Clinic in Tarzana. We see patients from across the San Fernando Valley, including Encino, Woodland Hills, Sherman Oaks, Reseda and Northridge.
This article is general medical information, not medical advice, and does not replace an individual consultation. Medication effects, suitability and dosing vary by person. Always follow the guidance of your prescribing provider, and seek emergency care for severe symptoms.
Written by: Contour Medical Clinic Editorial Team